However, given the significantly lesser frequency of these other oncogenic drivers (e.g., 3%–5% for ALK fusions in NSCLC; ref. 63), different strategies for training and model architecture may be needed to engineer robust model performance. Here, ALK is linked to non-small cell lung carcinoma.